CN118754965A - Glp-1和gip受体双重激动剂化合物及其应用 - Google Patents
Glp-1和gip受体双重激动剂化合物及其应用 Download PDFInfo
- Publication number
- CN118754965A CN118754965A CN202410666887.1A CN202410666887A CN118754965A CN 118754965 A CN118754965 A CN 118754965A CN 202410666887 A CN202410666887 A CN 202410666887A CN 118754965 A CN118754965 A CN 118754965A
- Authority
- CN
- China
- Prior art keywords
- amino acid
- acid residues
- glp
- ala
- acid residue
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/605—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Diabetes (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Endocrinology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biophysics (AREA)
- Toxicology (AREA)
- Biochemistry (AREA)
- Child & Adolescent Psychology (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Emergency Medicine (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010472577 | 2020-05-29 | ||
| CN2020104725778 | 2020-05-29 | ||
| CN202110335100X | 2021-03-29 | ||
| CN202110335100 | 2021-03-29 | ||
| PCT/CN2021/096568 WO2021239082A1 (zh) | 2020-05-29 | 2021-05-28 | Glp-1和gip受体双重激动剂化合物及其应用 |
| CN202180004912.4A CN114222755B (zh) | 2020-05-29 | 2021-05-28 | Glp-1和gip受体双重激动剂化合物及其应用 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202180004912.4A Division CN114222755B (zh) | 2020-05-29 | 2021-05-28 | Glp-1和gip受体双重激动剂化合物及其应用 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN118754965A true CN118754965A (zh) | 2024-10-11 |
Family
ID=78745631
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202410666887.1A Pending CN118754965A (zh) | 2020-05-29 | 2021-05-28 | Glp-1和gip受体双重激动剂化合物及其应用 |
| CN202410663771.2A Pending CN118530333A (zh) | 2020-05-29 | 2021-05-28 | Glp-1和gip受体双重激动剂化合物及其应用 |
| CN202180004912.4A Active CN114222755B (zh) | 2020-05-29 | 2021-05-28 | Glp-1和gip受体双重激动剂化合物及其应用 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202410663771.2A Pending CN118530333A (zh) | 2020-05-29 | 2021-05-28 | Glp-1和gip受体双重激动剂化合物及其应用 |
| CN202180004912.4A Active CN114222755B (zh) | 2020-05-29 | 2021-05-28 | Glp-1和gip受体双重激动剂化合物及其应用 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US12653865B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4159750A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP7858549B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR20230018395A (cg-RX-API-DMAC7.html) |
| CN (3) | CN118754965A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2021278157B2 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112022023834A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3180215A1 (cg-RX-API-DMAC7.html) |
| MX (1) | MX2022014368A (cg-RX-API-DMAC7.html) |
| TW (1) | TWI910174B (cg-RX-API-DMAC7.html) |
| WO (1) | WO2021239082A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20240118914A (ko) | 2021-01-20 | 2024-08-05 | 바이킹 테라퓨틱스 인코포레이티드 | 대사 및 간 질환 치료를 위한 조성물 및 방법 |
| CA3231953A1 (en) | 2021-09-15 | 2023-03-23 | Brian Lian | Compositions and methods for the treatment of metabolic and liver disorders |
| CN118103391A (zh) * | 2021-11-12 | 2024-05-28 | 福建盛迪医药有限公司 | Glp-1受体和gip受体双重激动剂的药物组合物及其用途 |
| CN116970063A (zh) * | 2022-04-29 | 2023-10-31 | 苏州星洲生物科技有限公司 | Glp-1/gip受体共激动剂、包含其的药物组合物及其用途 |
| CN117402219B (zh) * | 2022-07-13 | 2024-07-30 | 杭州中美华东制药有限公司 | Glp-1/gip双激动剂及其制备方法和用途 |
| CN115806593B (zh) * | 2022-09-23 | 2023-09-05 | 成都普康生物科技有限公司 | 一种脂肪酸链修饰的双受体激动剂及其用途 |
| CN116120425A (zh) * | 2022-12-27 | 2023-05-16 | 南京赛诺生物技术有限公司 | 一种glp-1/gip受体双重激动剂及其应用 |
| WO2024153090A1 (zh) * | 2023-01-17 | 2024-07-25 | 广东众生睿创生物科技有限公司 | 基于glp-1的三重激动剂 |
| CN118684758A (zh) * | 2023-03-23 | 2024-09-24 | 上海民为生物技术有限公司 | 肠促胰岛素类似物及其应用 |
| CN116496361B (zh) * | 2023-06-25 | 2023-09-15 | 北京科翔中升医药科技有限公司 | 氘代模拟肽gip和glp-1双受体激动剂药物及用途 |
| WO2025124473A1 (zh) | 2023-12-12 | 2025-06-19 | 江苏恒瑞医药股份有限公司 | Glp-1类似物治疗代谢疾病的方法及医药用途 |
| WO2025242218A1 (zh) * | 2024-05-24 | 2025-11-27 | 上海翰森生物医药科技有限公司 | 一种多肽激动剂,其制备方法及医药用途 |
| CN119390784B (zh) * | 2024-07-11 | 2026-06-30 | 中国药科大学 | 一种双激动多肽化合物及其医药用途 |
| CN118546214B (zh) * | 2024-07-11 | 2024-12-03 | 中国药科大学 | Glp-1r受体激动多肽化合物及其用途 |
Family Cites Families (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI362392B (en) | 2005-03-18 | 2012-04-21 | Novo Nordisk As | Acylated glp-1 compounds |
| EP2007804B1 (en) | 2006-04-20 | 2014-06-18 | Amgen, Inc | Glp-1 compounds |
| US20120329711A1 (en) | 2009-12-16 | 2012-12-27 | Nordisk A/S | Glp-1 receptor agonist compounds with a modified n-terminus |
| RU2013133803A (ru) | 2010-12-22 | 2015-01-27 | Маркадиа Байотек, Инк. | Способы лечения метаболических нарушений и ожирения при помощи пептидов на основе глюкагона, активных по отношению к рецепторам гип и гпп |
| KR102002783B1 (ko) | 2011-06-10 | 2019-07-24 | 베이징 한미 파마슈티컬 컴퍼니 리미티드 | 포도당 의존성 인슐리노트로핀 폴리펩타이드 유사물질, 이의 약학적 조성물 및 응용 |
| ES2602486T3 (es) | 2012-06-21 | 2017-02-21 | Indiana University Research And Technology Corporation | Análogos de glucagón que muestran actividad de receptor de GIP |
| CN104981186A (zh) | 2012-12-12 | 2015-10-14 | 意特发展有限公司 | 发泡器、混合器 |
| HUE035803T2 (en) | 2012-12-21 | 2018-05-28 | Sanofi Sa | Dual GLP1 / GIP or trigonal GLP1 / GIP / glucagon agonists |
| CN108271356A (zh) | 2014-09-24 | 2018-07-10 | 印第安纳大学研究及科技有限公司 | 肠降血糖素-胰岛素缀合物 |
| JP6581656B2 (ja) * | 2014-10-24 | 2019-09-25 | メルク・シャープ・アンド・ドーム・コーポレーションMerck Sharp & Dohme Corp. | グルカゴンおよびglp−1受容体のコアゴニスト |
| AR103242A1 (es) | 2015-01-09 | 2017-04-26 | Lilly Co Eli | Compuestos co-agonistas de gip y glp-1 |
| WO2016131893A1 (en) | 2015-02-18 | 2016-08-25 | Medimmune Limited | Incretin fusion polypeptides |
| JP6712323B2 (ja) | 2015-12-31 | 2020-06-17 | ハンミ ファーマシューティカル カンパニー リミテッド | グルカゴン、glp−1及びgip受容体のすべてに活性を有する三重活性体 |
| WO2017149070A1 (en) | 2016-03-03 | 2017-09-08 | Novo Nordisk A/S | Glp-1 derivatives and uses thereof |
| CA3062194A1 (en) | 2017-06-20 | 2018-12-27 | Amgen Inc. | Method of treating or ameliorating metabolic disorders using binding proteins for gastric inhibitory peptide receptor (gipr) in combination with glp-1 agonists |
| JP7250706B2 (ja) | 2017-06-21 | 2023-04-03 | アムジエン・インコーポレーテツド | 胃抑制ペプチド受容体(gipr)に対するアンタゴニスト結合タンパク質/glp-1受容体アゴニスト融合タンパク質を使用した代謝障害の治療又は寛解方法 |
| US20210087250A1 (en) | 2018-04-06 | 2021-03-25 | Cyprumed Gmbh | Pharmaceutical compositions for the transmucosal delivery of therapeutic peptides and proteins |
| TWI705820B (zh) | 2018-06-22 | 2020-10-01 | 美商美國禮來大藥廠 | Gip/glp1促效劑組合物 |
| AU2019309798A1 (en) | 2018-07-23 | 2021-02-11 | Eli Lilly And Company | Method of using a GIP/GLP1 co-agonist for diabetes |
| KR20250044806A (ko) | 2018-07-23 | 2025-04-01 | 일라이 릴리 앤드 캄파니 | 요법을 위한 gip/glp1 공효능제 사용 방법 |
| ES3068975T3 (en) | 2018-07-23 | 2026-06-03 | Lilly Co Eli | Gip/glp1 co-agonist compounds |
| EP3856768A2 (en) | 2018-09-24 | 2021-08-04 | Takeda Pharmaceutical Company Limited | Gip receptor agonist peptide compounds and uses thereof |
| US20220016215A1 (en) | 2018-09-24 | 2022-01-20 | Takeda Phaarmaceutical Company Limited | Gip receptor agonist peptide compounds and uses thereof |
| AU2020256648B2 (en) | 2019-04-11 | 2026-01-15 | Jiangsu Hansoh Pharmaceutical Group Co., Ltd. | Multi-receptor agonist and medical use thereof |
| CN111825758B (zh) | 2019-04-19 | 2024-11-22 | 上海翰森生物医药科技有限公司 | Glp-1和gip共激动剂化合物 |
| TW202120535A (zh) | 2019-11-15 | 2021-06-01 | 大陸商江蘇豪森藥業集團有限公司 | 受體雙重激動劑化合物及其醫藥組成物 |
| EP4069726A4 (en) | 2019-12-04 | 2024-03-20 | The Scripps Research Institute | GLP2 RECEPTOR AGONISTS AND METHOD OF USE |
| IL296592A (en) | 2020-03-25 | 2022-11-01 | Takeda Pharmaceuticals Co | Qd dosing of gip receptor agonist peptide compounds and uses thereof |
| TW202216746A (zh) | 2020-06-22 | 2022-05-01 | 印度商太陽製藥工業有限公司 | 長效型glp-1/gip雙重促效劑 |
| JP2023534130A (ja) | 2020-07-22 | 2023-08-08 | ノヴォ ノルディスク アー/エス | Glp-1受容体およびgip受容体共作動薬 |
| AU2021312323A1 (en) | 2020-07-22 | 2023-02-02 | Novo Nordisk A/S | Co-agonists at GLP-1 and GIP receptors suitable for oral delivery |
| CN116171164A (zh) | 2020-10-17 | 2023-05-26 | 太阳医药工业有限公司 | Glp-1/gip双重激动剂 |
| CA3213261A1 (en) | 2021-03-25 | 2022-09-29 | Jiandong Yuan | Gip and glp-1 dual receptor agonist, pharmaceutical composition, and use |
| AU2022289610A1 (en) | 2021-06-09 | 2024-01-25 | The Scripps Research Institute | Long-acting dual gip/glp-1 peptide conjugates and methods of use |
| CN115521368B (zh) | 2021-06-25 | 2024-08-23 | 江苏鸿永医药技术有限公司 | 毒蜥外泌肽-4衍生物 |
| WO2024192219A1 (en) | 2023-03-15 | 2024-09-19 | Viking Therapeutics, Inc. | Pharmaceutical compositions and methods for the treatment of metabolic and liver disorders |
| WO2025024788A1 (en) | 2023-07-27 | 2025-01-30 | Biomedit, Llc | Stabilized glp-1 peptides and dual agonist peptides against glp-1r and gipr and methods of use thereof |
-
2021
- 2021-05-28 CN CN202410666887.1A patent/CN118754965A/zh active Pending
- 2021-05-28 TW TW110119502A patent/TWI910174B/zh active
- 2021-05-28 JP JP2022571299A patent/JP7858549B2/ja active Active
- 2021-05-28 EP EP21812549.0A patent/EP4159750A4/en active Pending
- 2021-05-28 BR BR112022023834A patent/BR112022023834A2/pt unknown
- 2021-05-28 US US17/927,304 patent/US12653865B2/en active Active
- 2021-05-28 WO PCT/CN2021/096568 patent/WO2021239082A1/zh not_active Ceased
- 2021-05-28 KR KR1020227043237A patent/KR20230018395A/ko active Pending
- 2021-05-28 CN CN202410663771.2A patent/CN118530333A/zh active Pending
- 2021-05-28 CA CA3180215A patent/CA3180215A1/en active Pending
- 2021-05-28 CN CN202180004912.4A patent/CN114222755B/zh active Active
- 2021-05-28 AU AU2021278157A patent/AU2021278157B2/en active Active
- 2021-05-28 MX MX2022014368A patent/MX2022014368A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US20230190879A1 (en) | 2023-06-22 |
| CN114222755A (zh) | 2022-03-22 |
| EP4159750A4 (en) | 2023-10-18 |
| KR20230018395A (ko) | 2023-02-07 |
| JP7858549B2 (ja) | 2026-05-14 |
| AU2021278157B2 (en) | 2026-08-06 |
| JP2023526973A (ja) | 2023-06-26 |
| BR112022023834A2 (pt) | 2022-12-27 |
| WO2021239082A1 (zh) | 2021-12-02 |
| TWI910174B (zh) | 2026-01-01 |
| EP4159750A1 (en) | 2023-04-05 |
| CA3180215A1 (en) | 2021-12-02 |
| CN114222755B (zh) | 2024-06-11 |
| TW202144393A (zh) | 2021-12-01 |
| CN118530333A (zh) | 2024-08-23 |
| US12653865B2 (en) | 2026-06-16 |
| AU2021278157A1 (en) | 2022-11-24 |
| MX2022014368A (es) | 2022-12-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN114222755B (zh) | Glp-1和gip受体双重激动剂化合物及其应用 | |
| CN112351994B (zh) | 一种多受体激动剂及其医药用途 | |
| CN113383014B (zh) | 双受体重激动剂化合物及其药物组合物 | |
| CN111825758B (zh) | Glp-1和gip共激动剂化合物 | |
| CN118103391A (zh) | Glp-1受体和gip受体双重激动剂的药物组合物及其用途 | |
| AU2024291989A1 (en) | Glp-1, gip and gcg receptor triagonist and use thereof | |
| RU2848325C1 (ru) | Соединение с двойной агонистической активностью в отношении рецепторов glp-1 и gip и его применение | |
| HK40069563A (en) | Dual-agonist compound for both glp-1 and gip receptors and application thereof | |
| RU2816492C2 (ru) | Мультирецепторный агонист и его медицинское применение | |
| HK40069563B (en) | Dual-agonist compound for both glp-1 and gip receptors and application thereof | |
| HK40043112A (en) | Multi-receptor agonist and medical use thereof | |
| HK40051504A (en) | Dual receptor-acting agonist compounds and pharmaceutical composition thereof | |
| CA3297621A1 (en) | Glp-1, gip and gcg receptor triagonist and use thereof | |
| HK40043112B (en) | Multi-receptor agonist and medical use thereof | |
| TW202545982A (zh) | 胰島澱粉樣多肽類似物及其醫藥用途 | |
| HK40051504B (en) | Dual receptor-acting agonist compounds and pharmaceutical composition thereof | |
| EA053272B1 (ru) | Фармацевтическая композиция двойного агониста рецептора glp-1 и рецептора gip и ее применение |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |